Use of circulating tumor DNA (ctDNA) for early assessment of treatment response in patients with non-small cell lung cancer (NSCLC): A real-world (RW) analysis incorporating baseline ctDNA level and molecular response

被引：0
|
作者：
Gordon, Sean
Losic, Bojan
Quinn, Katie
Chang, Kyle
Liao, Jiemin
Chuang, Han-Yu
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-5573
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5573
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Use of circulating tumor DNA (ctDNA) for early assessment of treatment response in patients with advanced colorectal cancer (aCRC): A real-world (RW) analysis.
    Kasi, Pashtoon Murtaza
    Weipert, Caroline
    Nguyen, Tim
    Liao, Jiemin
    Zhang, Nicole
    Forbes, Shaun
    Gordon, Sean
    Tan, Benjamin R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 246 - 246
  • [2] Investigating racial inequities of circulating tumor DNA (ctDNA) use in patients with non-small cell lung cancer: A real world analysis
    D'Aiello, Angelica
    Narvel, Hiba
    Daylan, Ayse Ece Cali
    Atalla, Eleftheria
    Vikash, Sindhu
    Solomon, Sheila
    Cheng, Haiying
    Liu, Jianyou
    Xue, Xiaonan
    Halmos, Balazs
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] USE OF REAL-WORLD (RW) DATA TO ASSESS THE ABILITY OF CIRCULATING CELL-FREE TUMOR DNA (CTDNA) MOLECULAR RESPONSE TO ASSESS THERAPEUTIC OUTCOMES IN PATIENTS WITH NONSMALL CELL LUNG CANCER (NSCLC)
    Weipert, Caroline
    Drusbosky, Leylah
    Bucheit, Leslie
    Chang, Kyle
    Forbes, Shaun
    Gordon, Sean
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A7 - A7
  • [4] Early Assessment of Therapy Response in Non-Small Cell Lung Cancer (NSCLC) via Longitudinal ctDNA Analysis
    Yaung, S.
    Ma, X.
    Ju, C.
    Woestmann, C.
    Xi, L.
    Hinzmann, B.
    Thomas, M.
    Heussel, C.
    Lasitschka, F.
    Meister, M.
    Schneider, M.
    Herth, F.
    Muley, T.
    Wehnl, B.
    Palma, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S369 - S369
  • [5] Early assessment of therapy response in non-small cell lung cancer (NSCLC) via longitudinal ctDNA analysis.
    Ma, Xiaoju Max
    Ju, Christine
    Woestmann, Corinna
    Xi, Liu
    Yaung, Stephanie J.
    Hinzmann, Bernd
    Thomas, Michael
    Heussel, Claus Peter
    Lasitschka, Felix
    Meister, Michael
    Schneider, Marc
    Herth, Felix
    Muley, Thomas
    Wehnl, Birgit
    Palma, John F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] Impact of genomic alterations measured in circulating tumor DNA (ctDNA) on clinical response to telisotuzumab vedotin treatment in patients with non-small cell lung cancer (NSCLC)
    Camidge, D. Ross
    Baijal, Shobhit
    Vasilopoulos, Athanasios
    Ratajczak, Christine
    Looman, Jim
    Li, Martha
    Ansell, Peter J.
    Lu, Shun
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Prognostic Role of Circulating Tumor DNA (ctDNA) and Immune Cell Biomarkers in Non-Small Cell Lung Cancer (NSCLC)
    Chae, Y. K.
    Agte, S.
    Davis, A.
    Pan, A.
    Simon, N.
    Mohindra, N.
    Villaflor, V.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2242 - S2242
  • [8] Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with advanced non-small cell lung cancer (NSCLC).
    Dagogo-Jack, Ibiayi
    Bernicker, Eric
    Li, Tianhong
    Wang, Victoria
    Ross, Jeffrey S.
    Young, Lauren
    Stephens, Philip J.
    Chung, Jon
    Shaw, Alice Tsang
    Ali, Siraj Mahamed
    Miller, Vincent A.
    Schrock, Alexa Betzig
    Spigel, David R.
    Ou, Sai-Hong Ignatius
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [9] Quantification of tumor fraction and outcomes association in a real-world non-small cell lung cancer (NSCLC) cohort using a tissue agnostic epigenomic circulating tumor DNA (ctDNA) assay
    Wienke, Sara
    Gordon, Sean
    Liang, Samantha
    Wang, Jing
    Barnett, Reagan
    Chang, Kyle
    Zhang, Shile
    Espenschied, Carin R.
    Quinn, Katie
    Banks, Kimberly
    [J]. CANCER RESEARCH, 2024, 84 (06)
  • [10] Early plasma circulating tumor DNA (ctDNA) changes to predict response to first-line pembrolizumab plus /- chemotherapy in non-small cell lung cancer (NSCLC).
    Ricciuti, Biagio
    Champagne, Christine
    Jones, Greg
    Lazarus, Tadd Scott
    Adeni, Anika E.
    Cheng, Michael L.
    Oxnard, Geoffrey R.
    Awad, Mark M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345